FGFR1 and non-small cell lung carcinoma: A study from 2014 reported FGFR1 activation as a mechanism of resistance to the irreversible second-generation EGFR inhibitor afatinib in PC9 cells (a NSCLC cell line harbouring EGFR Ex19del) [56].